Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
67.06
-2.15 (-3.11%)
Streaming Delayed Price
Updated: 2:42 PM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
↗
November 01, 2024
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
↗
November 01, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 31, 2024
Via
Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
↗
October 31, 2024
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.
Via
Chartmill
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
↗
October 30, 2024
Via
Benzinga
Unveiling 12 Analyst Insights On Halozyme Therapeutics
↗
October 25, 2024
Via
Benzinga
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
↗
October 22, 2024
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.
Via
Chartmill
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
↗
October 11, 2024
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Via
Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
↗
October 10, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts
↗
October 04, 2024
Via
Benzinga
NASDAQ:HALO is showing good growth, while it is not too expensive.
↗
September 19, 2024
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.
Via
Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
September 19, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
↗
September 13, 2024
Via
Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
↗
August 29, 2024
NASDAQ:HALO is showing good growth, while it is not too expensive.
Via
Chartmill
Top 2 Health Care Stocks That May Plunge In August
↗
August 26, 2024
Via
Benzinga
How Is The Market Feeling About Halozyme Therapeutics?
↗
August 20, 2024
Via
Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
↗
September 13, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
↗
September 13, 2024
Via
Benzinga
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
August 28, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying.
Via
Chartmill
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
↗
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
↗
August 08, 2024
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.
Via
Chartmill
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
↗
August 01, 2024
Via
Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
↗
August 01, 2024
Via
Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
↗
August 08, 2024
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 06, 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
↗
August 06, 2024
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Via
Investor's Business Daily
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
↗
August 06, 2024
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
Via
Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
↗
August 05, 2024
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
↗
August 04, 2024
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
